Dementia/Biogen: causal controversy means investors must take a stance
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares downCoronavirus pandemic
Consulta l'articolo completo a questo indirizzo
https://www.ft.com/content/db5d5c65-344f-4138-94cb-fb12ac916281?segmentId=776b81d7-dd92-c731-e669-99cdd37d3a96#myft:my-news:rss
